NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/22/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,830.01 mln
Float132 mln
Earnings Date08/12/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
0.04
Debt-free
ROE
-25.29
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Vaxcyte is a clinical-stage biotechnology company focused on developing next-generation vaccines to protect against serious bacterial infections. Its pipeline includes several investigational vaccines targeting pneumococcal disease in both children and adults, as well as candidates aimed at Group A Streptococcus, the bacteria behind gum disease, and dysentery-causing Shigella. Founded in 2013 and based in San Carlos, California, the company was previously known as SutroVax before rebranding in 2020.
